Skip to main content
Oxurion NV logo

Oxurion NV — Investor Relations & Filings

Ticker · OXUR ISIN · BE0974487192 LEI · 549300VWY8KVDFKLDM59 BR Professional, scientific and technical activities
Open in API
Filings indexed 1,031 across all filing types
Latest filing 2018-01-26 Regulatory Filings
Country BE Belgium
Listing BR OXUR

About Oxurion NV

https://oxurion.com/

Oxurion NV is a company focused on acquiring majority stakes in European pharmaceutical subcontractors. Its strategy is to build an integrated group of contract service providers to support healthcare stakeholders. A key asset in its portfolio is a majority stake in Axiodis CRO, a contract research organization specializing in biometrics. This investment-based business model represents a strategic pivot from the company's former focus on the internal research and development of therapies for retinal diseases such as Geographic Atrophy (GA) and Age-related Macular Degeneration (AMD).

Recent filings

Filing Released Lang Actions
THR NVS transparency statement 26012018 EN.pdf
Regulatory Filings Classification · 98% confidence The document is explicitly labeled as a "Press release Regulated Information / Transparency Statement" dated January 26, 2018. The core content details a change in shareholding percentage (Novartis holding 5.69% of equity capital) due to a capital increase, which is a notification required under Belgian transparency legislation. This type of announcement, reporting changes in significant share ownership or voting rights, directly aligns with the definition of Major Shareholding Notification (MRQ). While it involves capital structure changes, the primary focus is the notification of the new ownership threshold crossing, making MRQ the most precise fit over CAP or DVA. It is not a full report (10-K, IR) or a general regulatory filing (RNS), but a specific disclosure about share ownership.
2018-01-26 English
THR NVS transparency statement 26012018 NL.pdf
Major Shareholding Notification Classification · 98% confidence The document is titled "Persbericht Gereglementeerde Informatie / Transparantieverklaring" (Press Release Regulated Information / Transparency Declaration) and is dated January 26, 2018. The core content reports that ThromboGenics NV received a transparency declaration from Novartis Pharma AG, stating that Novartis controls 5.69% of ThromboGenics' capital. This is a mandatory disclosure under Belgian transparency legislation regarding significant shareholdings crossing a threshold. This directly corresponds to the definition of Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership levels (crossing thresholds). Although it is a press release, its specific content mandates the MRQ classification over the general RPA or RNS.
2018-01-26 Dutch
Press release decisiont to stop CIRCLE study
Legal Proceedings Report Classification · 99% confidence The document is explicitly labeled as a "Press Release / Regulated Information / Inside Information." It announces a specific operational decision: the discontinuation of patient recruitment for a Phase II clinical study (CIRCLE study) due to slow recruitment rates and the redirection of resources. This type of announcement, detailing a material business event that is not a full financial report (like 10-K or IR), a management change (MANG), or a dividend declaration (DIV), typically falls under general regulatory announcements or press releases. It is not an Earnings Release (ER) as it does not contain period financial results. It is not an Audit Report (AR) or Interim Report (IR). Since it is a specific, time-sensitive operational update disseminated via a press release format, and it doesn't fit the highly specific categories like DIRS, DIV, or CAP, the most appropriate classification is the general regulatory announcement category, RNS (Regulatory Filings), which serves as a fallback for material press releases that don't fit elsewhere. Given the length (5729 chars) and content (a full announcement, not just a notice that a report is attached), it is not an RPA.
2017-12-08 English
Meeting minutes of the extraordinary shareholders meeting on November 20, 2017 (D).pdf
AGM Information Classification · 97% confidence The document is a notarial deed ('akte') detailing proceedings of an 'buitengewone algemene vergadering der aandeelhouders' (Extraordinary General Meeting of Shareholders) for the company 'ThromboGenics'. The agenda explicitly concerns 'UITGIFTE WARRANTENPLAN 2017' (Issuance of Warrant Plan 2017) and 'KAPITAALVERHOGING IN GELD MET OPHEFFING VOORKEURRECHT' (Capital Increase in Cash with Waiver of Pre-emptive Rights). This type of formal meeting document, which records decisions made regarding capital structure and shareholder votes, aligns best with the general category for shareholder meeting materials, specifically those involving significant corporate actions. Since it is a formal record of an Extraordinary General Meeting (EGM) concerning capital changes, it is closely related to AGM materials, but the core content is the formal resolution of a meeting. Given the options, 'AGM-R' (AGM Information) is the closest fit for formal shareholder meeting minutes/records, even if it's an EGM, as it captures the formal proceedings and resolutions of a general assembly. It is not a standard 10-K, ER, or IR. It is a formal record of a meeting, not just a presentation (IP) or a simple announcement (RPA).
2017-12-07 Dutch
meeting minutes THR EGM 30102017.pdf
AGM Information Classification · 98% confidence The document text explicitly mentions 'BUITENGEWONE ALGEMENE VERGADERING' (Extraordinary General Meeting) and details the proceedings, including the verification of the attendance list, the bureau's role, and the presentation by the Chairman regarding the company's capital structure. This content is characteristic of the official minutes or documentation related to a shareholder meeting. Since the definition for AGM-R covers 'Presentations and materials shared during the Annual General Meeting (AGM)', and this document details an Extraordinary General Meeting (EGM) which falls under the general scope of shareholder meetings, AGM-R is the most appropriate classification, even though it is an EGM rather than an AGM. It is not a proxy statement (PSI) as it is the record of the meeting itself, not the solicitation material beforehand.
2017-11-23 Dutch
3_THR Rechten Aandeelhouder (EGM 201117).pdf
Proxy Solicitation & Information Statement Classification · 98% confidence The document text discusses the rights of shareholders regarding placing items on the agenda and submitting written questions prior to a 'bijzondere algemene vergadering' (special general meeting) scheduled for November 20, 2017. It details procedures, deadlines (like the registration date and question submission deadline), and the rights to ask questions to directors and the commissioner. This content is directly related to the procedures and information provided to shareholders in preparation for a general meeting, which aligns perfectly with the definition of Proxy Solicitation & Information Statement (PSI). While it relates to a general meeting, it is procedural information for shareholders rather than the final voting results (DVA) or the AGM presentation itself (AGM-R).
2017-10-31 Dutch

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.